{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:49:40Z","timestamp":1793414980603,"version":"4.5.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2024,8,13]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Observational studies report that \u03b2-blocker use may be associated with reduced risk of COPD exacerbations. However, a recent trial reported that metoprolol did not reduce COPD exacerbations and increased COPD exacerbations requiring hospital admission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To test whether bisoprolol decreased COPD exacerbations in people with COPD at high risk of exacerbations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>The Bisoprolol in COPD Study (BICS) was a double-blind placebo-controlled randomized clinical trial conducted in 76 UK sites (45 primary care clinics and 31 secondary clinics). Patients with COPD who had at least moderate airflow obstruction on spirometry (ratio of forced expiratory volume in the first second of expiration [FEV<jats:sub>1<\/jats:sub>] to forced vital capacity &amp;amp;lt;0.7; FEV<jats:sub>1<\/jats:sub> &amp;amp;lt;80% predicted) and at least 2 COPD exacerbations treated with oral corticosteroids, antibiotics, or both in the prior 12 months were enrolled from October 17, 2018, to May 31, 2022. Follow-up concluded on April 18, 2023.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Patients were randomly assigned to bisoprolol (n\u2009=\u2009261) or placebo (n\u2009=\u2009258). Bisoprolol was started at 1.25 mg orally daily and was titrated as tolerated during 4 sessions to a maximum dose of 5 mg\/d, using a standardized protocol.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary clinical outcome was the number of patient-reported COPD exacerbations treated with oral corticosteroids, antibiotics, or both during the 1-year treatment period. Safety outcomes included serious adverse events and adverse reactions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Although the trial planned to enroll 1574 patients, recruitment was suspended from March 16, 2020, to July 31, 2021, due to the COVID-19 pandemic. Two patients in each group were excluded postrandomization. Among the 515 patients (mean [SD] age, 68 [7.9] years; 274 men [53%]; mean FEV<jats:sub>1<\/jats:sub>, 50.1%), primary outcome data were available for 514 patients (99.8%) and 371 (72.0%) continued taking the study drug. The primary outcome of patient-reported COPD exacerbations treated with oral corticosteroids, antibiotics, or both was 526 in the bisoprolol group, with a mean exacerbation rate of 2.03\/y, vs 513 exacerbations in the placebo group, with a mean exacerbation rate of 2.01\/y. The adjusted incidence rate ratio was 0.97 (95% CI, 0.84-1.13; <jats:italic>P<\/jats:italic>\u2009=\u2009.72). Serious adverse events occurred in 37 of 255 patients in the bisoprolol group (14.5%) vs 36 of 251 in the placebo group (14.3%; relative risk, 1.01; 95% CI, 0.62-1.66; <jats:italic>P<\/jats:italic>\u2009=\u2009.96).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Among people with COPD at high risk of exacerbation, treatment with bisoprolol did not reduce the number of self-reported COPD exacerbations requiring treatment with oral corticosteroids, antibiotics, or both.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>isrctn.org Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.isrctn.com\/ISRCTN10497306\">ISRCTN10497306<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jama.2024.8771","type":"journal-article","created":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T13:30:46Z","timestamp":1716125446000},"page":"462","source":"Crossref","is-referenced-by-count":38,"title":["Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation"],"prefix":"10.1001","volume":"332","author":[{"given":"Graham","family":"Devereux","sequence":"first","affiliation":[{"name":"Liverpool School of Tropical Medicine, Liverpool, United Kingdom"},{"name":"Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, United Kingdom"},{"name":"Liverpool University Hospitals Foundation NHS Trust, University Hospital Aintree, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonaidh","family":"Cotton","sequence":"additional","affiliation":[{"name":"Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mintu","family":"Nath","sequence":"additional","affiliation":[{"name":"Medical Statistics Team, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"McMeekin","sequence":"additional","affiliation":[{"name":"School of Health & Wellbeing, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Campbell","sequence":"additional","affiliation":[{"name":"Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rekha","family":"Chaudhuri","sequence":"additional","affiliation":[{"name":"School of Infection & Immunity, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gourab","family":"Choudhury","sequence":"additional","affiliation":[{"name":"Royal Infirmary of Edinburgh, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"De Soyza","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shona","family":"Fielding","sequence":"additional","affiliation":[{"name":"Medical Statistics Team, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Gompertz","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Haughney","sequence":"additional","affiliation":[{"name":"Centre of Academic Primary Care, University of Aberdeen, Aberdeen, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Medical Statistics Team, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"MacLennan","sequence":"additional","affiliation":[{"name":"Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyn","family":"Morice","sequence":"additional","affiliation":[{"name":"Cardiovascular and Respiratory Studies, Castle Hill Hospital, Hull, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Norrie","sequence":"additional","affiliation":[{"name":"Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh BioQuarter, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Price","sequence":"additional","affiliation":[{"name":"Centre of Academic Primary Care, University of Aberdeen, Aberdeen, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Short","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Ninewells Hospital, Dundee, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorgen","family":"Vestbo","sequence":"additional","affiliation":[{"name":"Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Walker","sequence":"additional","affiliation":[{"name":"Liverpool University Hospitals Foundation NHS Trust, University Hospital Aintree, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jadwiga","family":"Wedzicha","sequence":"additional","affiliation":[{"name":"Imperial College London, National Heart and Lung Institute, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wilson","sequence":"additional","affiliation":[{"name":"Norwich Medical School, University of East Anglia, Norwich, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Health & Wellbeing, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Lipworth","sequence":"additional","affiliation":[{"name":"Ninewells Hospital and Medical School, University of Dundee, Dundee, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10258","key":"joi240066r2","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","journal-title":"Lancet"},{"issue":"5 pt 1","key":"joi240066r3","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1164\/ajrccm.157.5.9709032","article-title":"Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.","volume":"157","author":"Seemungal","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"joi240066r4","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1136\/thx.2005.040527","article-title":"Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.","volume":"60","author":"Soler-Catalu\u00f1a","year":"2005","journal-title":"Thorax"},{"issue":"1","key":"joi240066r5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13561-021-00329-9","article-title":"Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review.","volume":"11","author":"Guti\u00e9rrez Villegas","year":"2021","journal-title":"Health Econ Rev"},{"issue":"1","key":"joi240066r6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00222-2018","article-title":"A systematic review of how patients value COPD outcomes.","volume":"52","author":"Zhang","year":"2018","journal-title":"Eur Respir J"},{"issue":"4","key":"joi240066r9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858","article-title":"Cardioselective beta-blockers for chronic obstructive pulmonary disease.","volume":"2005","author":"Salpeter","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"joi240066r10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113048","article-title":"Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies.","volume":"9","author":"Du","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"joi240066r11","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/archinternmed.2010.112","article-title":"Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease.","volume":"170","author":"Rutten","year":"2010","journal-title":"Arch Intern Med"},{"issue":"1","key":"joi240066r12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/thoraxjnl-2015-207251","article-title":"\u00df-Blockers are associated with a reduction in COPD exacerbations.","volume":"71","author":"Bhatt","year":"2016","journal-title":"Thorax"},{"issue":"8","key":"joi240066r13","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1056\/NEJM199808203390801","article-title":"Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction.","volume":"339","author":"Gottlieb","year":"1998","journal-title":"N Engl J Med"},{"key":"joi240066r14","doi-asserted-by":"publisher","first-page":"d2549","DOI":"10.1136\/bmj.d2549","article-title":"Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study.","volume":"342","author":"Short","year":"2011","journal-title":"BMJ"},{"issue":"24","key":"joi240066r15","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1056\/NEJMoa1908142","article-title":"Metoprolol for the prevention of acute exacerbations of COPD.","volume":"381","author":"Dransfield","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"joi240066r16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s13063-022-06226-8","article-title":"Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS).","volume":"23","author":"Cotton","year":"2022","journal-title":"Trials"},{"issue":"6","key":"joi240066r20","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1183\/09031936.04.00014304","article-title":"Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper.","volume":"23","author":"Celli","year":"2004","journal-title":"Eur Respir J"},{"issue":"3","key":"joi240066r21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S2213-2600(14)70001-3","article-title":"Minimum clinically important difference for the COPD Assessment Test: a prospective analysis.","volume":"2","author":"Kon","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"6","key":"joi240066r22","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1378\/chest.85.6.751","article-title":"The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes.","volume":"85","author":"Mahler","year":"1984","journal-title":"Chest"},{"issue":"3","key":"joi240066r23","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1164\/rccm.201310-1863PP","article-title":"Minimal clinically important differences in pharmacological trials.","volume":"189","author":"Jones","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"joi240066r24","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry.","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"issue":"21","key":"joi240066r25","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.106.620039","article-title":"Variable impact of combining fatal and nonfatal end points in heart failure trials.","volume":"114","author":"Skali","year":"2006","journal-title":"Circulation"},{"issue":"1","key":"joi240066r26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00408-010-9272-1","article-title":"Cough hypersensitivity syndrome: a distinct clinical entity.","volume":"189","author":"Morice","year":"2011","journal-title":"Lung"},{"issue":"12","key":"joi240066r28","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease.","volume":"363","author":"Hurst","year":"2010","journal-title":"N Engl J Med"},{"issue":"15","key":"joi240066r29","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1001\/jama.2018.14432","article-title":"Effect of theophylline as adjunct to inhaled corticosteroids on exacerbations in patients with COPD: a randomized clinical trial.","volume":"320","author":"Devereux","year":"2018","journal-title":"JAMA"},{"issue":"3","key":"joi240066r31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/sj.bjp.0706048","article-title":"The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.","volume":"144","author":"Baker","year":"2005","journal-title":"Br J Pharmacol"},{"issue":"2","key":"joi240066r32","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/cdr.2013.31.issue-2","article-title":"Cardio-selective beta-blocker: pharmacological evidence and their influence on exercise capacity.","volume":"31","author":"Ladage","year":"2013","journal-title":"Cardiovasc Ther"},{"issue":"3","key":"joi240066r33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/heartjnl-2013-304769","article-title":"Effects of intravenous and oral \u00df-blockade in persistent asthmatics controlled on inhaled corticosteroids.","volume":"100","author":"Short","year":"2014","journal-title":"Heart"},{"issue":"12","key":"joi240066r34","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/qjmed\/hcx155","article-title":"Cardio-pulmonary interactions with beta-blockers and inhaled therapy in COPD.","volume":"110","author":"Jabbal","year":"2017","journal-title":"QJM"},{"issue":"9146","key":"joi240066r35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.","volume":"353","author":"CIBIS-II Investigators and Committees","year":"1999","journal-title":"Lancet"},{"key":"joi240066r30","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511973420","volume-title":"Negative Binomial Regression","author":"Hilbe","year":"2011","edition":"2nd ed"},{"key":"joi240066r1","unstructured":"World Health Organization. The top 10 causes of death. Published December 9, 2020. Accessed April 30, 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death"},{"key":"joi240066r7","unstructured":"National Institute for Health and Care Excellence. Acute coronary syndromes. Published November 18, 2020. Accessed April 30, 2024. https:\/\/www.nice.org.uk\/guidance\/ng185"},{"key":"joi240066r8","unstructured":"National Institute for Health and Care Excellence. Chronic heart failure in adults: diagnosis and management. Published September 12, 2018. Accessed April 30, 2024. https:\/\/www.nice.org.uk\/guidance\/ng106"},{"key":"joi240066r17","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2024 report). Accessed April 30, 2024. https:\/\/goldcopd.org\/wp-content\/uploads\/2024\/02\/GOLD-2024_v1.2-11Jan24_WMV.pdf"},{"key":"joi240066r18","unstructured":"Scottish Intercollegiate Guidelines Network. Sign 147: management of chronic heart failure. Accessed April 30, 2024. https:\/\/www.sign.ac.uk\/assets\/sign147.pdf"},{"key":"joi240066r19","unstructured":"National Institute for Care and Health Excellence (NICE) British National Formulary. 2023 Bisoprolol-fumarate. Accessed April 30, 2024. https:\/\/bnf.nice.org.uk\/drugs\/bisoprolol-fumarate\/"},{"key":"joi240066r27","unstructured":"MedDRA. Introductory guide MedDRA version 24.1. Accessed April 30, 2024. https:\/\/alt.meddra.org\/files_acrobat\/intguide_24_1_English.pdf"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2819083\/jama_devereux_2024_oi_240066_1722611498.87836.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T15:15:34Z","timestamp":1723562134000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2819083"}},"subtitle":["The BICS Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,8,13]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2024.8771","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,13]]}}}